Filing Flows › Chemours (CC) › Guidance & outlook

Chemours (CC) guidance and outlook

Chemours (CC) lowered its guidance on Nov 2, 2026: Revenue +5% to +10% for Q4 2026; EBITDA $160M–$185M for Q4 2026; Capital expenditures $75.0M–$85.0M for Q4 2026; Revenue +2% for FY2026. Chemours' 10-Q filed Nov 5, 2026 makes 34 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 2, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business.
• In 2018, we set forth ambitious Corporate Responsibility Commitment ("CRC") goals that we aim to achieve by 2030.
• other items not considered indicative of our ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the Memorandum of Understanding (“MOU”) that were previously excluded from Adjusted EBITDA.
• We expect the liquidity from these sources will provide adequate funds to support the cash needs of our businesses through at least the end of November 2027.
• There can be no assurances that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materially impacted by market conditions.
• Our outlook has been changed from negative to stable, reflecting expectations for continued earnings improvement and free cash flow generation, along with net proceeds from asset sales to be applied toward debt reduction.
• On April 16, 2025, S&P Global affirmed our BB- credit rating with negative outlook.
• We currently anticipate that we will remain in compliance with applicable covenants under the Credit Agreement through at least November 2027.
• As a result of the Company’s 2026 debt-related activity, anticipated annual interest expense is expected to decrease approximately $3 million.
• Over the course of the next 12 months and beyond, we anticipate making significant cash payments for known contractual and other obligations, which we expect to fund through cash generated from operations, available cash (including restricted cash), receivables securitization, and our existing debt financing arrangements.
• Other legal settlements - In addition to the legal items noted above, we have other legal settlements that we expect to pay within the next 12 months and beyond.
• We expect that the remaining restricted cash received pursuant to the PFAS Insurance MOU will fully fund our New Jersey annual settlement payment obligations through at least 2030.

Chemours' latest quarter

Questions

Did Chemours raise or lower its guidance?

Chemours (CC) lowered its guidance on Nov 2, 2026: Revenue +5% to +10% for Q4 2026; EBITDA $160M–$185M for Q4 2026; Capital expenditures $75.0M–$85.0M for Q4 2026; Revenue +2% for FY2026.

What does Chemours expect?

Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. In 2018, we set forth ambitious Corporate Responsibility Commitment ("CRC") goals that we aim to achieve by 2030. other items not considered indicative of our ongoing operational performance and expected to occur infrequently, including certain litigation related and environmental charges and Qualified Spend reimbursable by DuPont and/or Corteva as part of our cost-sharing agreement under the terms of the Memorandum o

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.